1-6 of 6
Christopher A. Eide
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia

Rucha V. Modak, Katia G. de Oliveira Rebola, John McClatchy, Mona Mohammadhosseini, Alisa Damnernsawad, Stephen E. Kurtz, Christopher A. Eide, Guanming Wu, Ted Laderas, Tamilla Nechiporuk, Marina A. Gritsenko, Joshua R. Hansen, Chelsea Hutchinson, Sara J.C. Gosline, Paul Piehowski, Daniel Bottomly, Nicholas Short, Karin Rodland, Shannon K. McWeeney, Jeffrey W. Tyner, Anupriya Agarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (10): 2245–2259.
https://doi.org/10.1158/1078-0432.CCR-23-2654
Published: 15 May 2024
View article titled, Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia
Open the PDF for Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases

Olivia M. Lucero, Ji-Ann Lee, Jenna Bowman, Kara Johnson, Gopal Sapparapu, John K. Thomas, Guang Fan, Bill H. Chang, Karina Thiel-Klare, Christopher A. Eide, Craig Okada, Mike Palazzolo, Evan Lind, Yoko Kosaka, Brian J. Druker, Nicholas Lydon, Peter M. Bowers
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4230–4241.
https://doi.org/10.1158/1078-0432.CCR-22-0906
Published: 13 October 2023
View article titled, Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases
Open the PDF for Patient-Specific Targeting of the T-Cell Receptor Variable Region as a Therapeutic Strategy in Clonal T-Cell Diseases in another window
Includes: Supplementary data
Journal Articles

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer

Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian J. Druker, Thomas O'Hare, Marc Ladanyi, Monika A. Davare
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2351–2358.
https://doi.org/10.1158/1078-0432.CCR-15-2013
Published: 12 May 2016
View article titled, A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <em>ROS1</em>-Rearranged Lung Cancer
Open the PDF for A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with <em>ROS1</em>-Rearranged Lung Cancer in another window
Includes: Supplementary data
Journal Articles

The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I

Julia E. Maxson, Samuel B. Luty, Jason D. MacManiman, Jason C. Paik, Jason Gotlib, Peter Greenberg, Swaleh Bahamadi, Samantha L. Savage, Melissa L. Abel, Christopher A. Eide, Marc M. Loriaux, Emily A. Stevens, Jeffrey W. Tyner
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (3): 757–764.
https://doi.org/10.1158/1078-0432.CCR-14-3100
Published: 31 January 2016
View article titled, The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I
Open the PDF for The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I in another window
Includes: Supplementary data
Journal Articles

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

Anupriya Agarwal, Ryan J. MacKenzie, Raffaella Pippa, Christopher A. Eide, Jessica Oddo, Jeffrey W. Tyner, Rosalie Sears, Michael P. Vitek, María D. Odero, Dale J. Christensen, Brian J. Druker
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (8): 2092–2103.
https://doi.org/10.1158/1078-0432.CCR-13-2575
Published: 15 April 2014
View article titled, Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
Open the PDF for Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia

Thomas O'Hare, Michael W.N. Deininger, Christopher A. Eide, Tim Clackson, Brian J. Druker
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (2): 212–221.
https://doi.org/10.1158/1078-0432.CCR-09-3314
Published: 16 January 2011
View article titled, Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
Open the PDF for Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia in another window